The LymeX Diagnostics Prize is projected to be an over $10 million prize competition to accelerate the development of Lyme disease diagnostics. The competition will call on scientific, technical, and clinical experts to submit innovative detection methods that will advance Lyme disease diagnostics. The ultimate goal of the competition is to develop diagnostics submitted to the Food and Drug Administration for review that detect active infection by Lyme disease-causing bacteria in people.
The multiyear competition is expected to launch in spring 2022, with the following anticipated phase structure.
- Phase 1 – Open call for concepts
- Phases 2 and 3 – Development, prototyping, and validation
HHS is conducting this prize competition under the authority of and in accordance with the America COMPETES Act, as amended, 15 U.S.C. § 3719.
The Lyme Innovation Accelerator (LymeX), a partnership between the U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation, is the world’s largest public-private partnership for Lyme disease. LymeX, as a component of a larger moonshot, is identifying, developing, and implementing advancements in Lyme disease care — including next-generation diagnostics.
Total anticipated prize pool: over $10 million
Anticipated Phase 1 prize pool: $1 million
It is anticipated that the LymeX Diagnostics Prize will offer $10 million in prize funds for the initial phases outlined below. Based on availability of future funds, an additional $10 million may be allocated for a total of $20 million in prize funds.
Final prize amounts will be determined at the discretion of HHS, and are subject to availability and obligation of future funds. Details regarding the amount and distribution of both monetary and non-monetary prizes will be posted upon launch of Phase 1, at Challenge.gov and at LymeXDiagnosticsPrize.com.